key: cord-0731025-qs3zswm8 authors: Munoz-Rodriguez, JR; Gomez-Romero, FJ; Perez-Ortiz, JM; Lopez-Juarez, P; Santiago, JL; Serrano-Oviedo, L; Redondo-Calvo, FJ title: Characteristics and risk factors associated with mortality in a multicenter Spanish cohort of patients with COVID-19 pneumonia date: 2021-03-09 journal: Arch Bronconeumol DOI: 10.1016/j.arbres.2021.02.021 sha: 2b9ef5b84bada92e2a7453a8d00fb7c3cf50aeab doc_id: 731025 cord_uid: qs3zswm8 INTRODUCTION: Spain is one of the countries with the highest number of COVID-19 patients. Unfortunately, few data for regions are available. OBJETIVES: This study aimed to describe the characteristics and independent risk factors associated with COVID-19 mortality in Castilla-La Mancha, Spain. Methods: Cohort and multicenter study in all 14 public hospitals of the Castilla-La Mancha Health Service. Baseline characteristics, preexisting comorbidities, symptoms, clinical features and treatments were included. Multivariable logistic regression was used to evaluate factors associated with death and Kaplan-Meier test to examine survival probability. Statistical significance was considered with p <0.05 (95% CI). SPSS (version 24.0 for Windows) and R 4.0.2 (R Statistics) software were used. Results: The cohort comprised 12,126 patients sequentially attended between February 11 and May 11, 2020. The mean age of patients was 66.4 years; 5,667 (46.7%) were women. Six protective factors against exitus were defined: female sex, anosmia, cough, chloroquine and azithromycin. The risk factors were: age over 50, obesity, cardiac pathology, fever, dyspnea, lung infiltrates, lymphopenia, D-dimer above 1000 ng/mL, and mechanical ventilation requirement. Survival analysis showed higher survival rate in women (75.7%) than men (72.1%). Cumulative survival was 87.5% for non-hospitalized patients, 70.2% for patients admitted to hospital and 61.2% in ICU patients. Additionally, survival probability decreased with increasing age range Conclusion: Determination of protective or death-promoting factors could be useful to stratify patients by severity criteria and to improve COVID-19 care management. Since its origin in Wuhan in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly in many of the world's countries. Spain has one of the highest number of affected patients in the world 1,2 . Given the potential severity of the disease, it is essential to study the parameters that may be affected in different population groups, to help to predict the demand for health resources and to design effective mitigation protocols 3 . Some of the risk factors for severe disease and death have already been estimated in published case series [4] [5] [6] , although the details of the clinical course of the disease have not yet been well described 4 . Numerous demographic studies have been conducted worldwide, showing differences and similarities in clinical appearance between regions 1, [7] [8] [9] [10] . This highlights the importance of conducting studies in different world-areas 11 . Castilla-La Mancha is located in the center of the Iberian Peninsula, near Madrid, and has been one of the most affected regions in Spain with 18,869 confirmed COVID-19 patients since the beginning of the pandemic. Furthermore, it has one of the highest seroprevalence rates in the country (10-13.6%) 2 . In this study, we show data of patients admitted to all public hospitals in Castilla-La Mancha for 90 days, during the first peak of the pandemic in the region. We describe the characteristics and explore the risk factors associated with mortality, in order to improve our knowledge in the diagnosis, clinical evolution and prognosis and thus to facilitate improvements in the treatment of this disease. This prospective, multicenter, cohort study was carried out from February 11 to May 11, 2020. It was conducted at all 14 public hospitals of the Health Service of Castilla-La Mancha (SESCAM), Spain, covering 30,680 square miles and serving to 2 million residents in urban, suburban, and rural areas. None of the hospitals were specifically designated for COVID-19 and the distribution of patients in the centers was similar to under normal conditions. Participants were adult patient (>18 years old) transferred between hospitals or attended in the referral hospital, meeting one or more laboratory criteria and/or one or more clinical criteria of suspected COVID-19. Laboratory criteria: Positive detection of 1) 2019-nCoV nucleic acid by real-time Polymerase Chain Reaction (PCR). 2) IgM from human serum with rapid test for SARS-CoV-2. Clinical criteria with COVID-19: 1) Acute respiratory infection with fever, cough or dyspnea. 2) Radiographic characteristics of pneumonia, such as multiple ground-glass shadows, infiltrative shadows and consolidation in both lungs. 3) Other symptoms such as odynophagia, anosmia, ageusia, vomiting, muscle aches, diarrhea, chest pain or headaches. Non-criteria inclusion for patients, subsequent admissions, transfers or duplicates for the same patient, and pediatric patient (<18 years old) were excluded in our study. General Directorate of Public Health (GDPH) promoted this study and established a trained team of thirty physicians for the protocolized extraction and collection of data from electronic medical records, using a standard data form for epidemiological surveillance, within the health information system. These physicians performed this operation after a daily updating of the admitted list in each hospital. After that, three clinical coordinators supervised and checked for errors the data collection in the GDPH. guidelines. We reported the distribution of characteristics overall by gender and death. Continuous variables were presented as mean with standard deviation (SD) or median with interquartile range (IQR), and categorical variables as n (%). Baseline characteristics were compared using the Student t test or Mann Whitney's U test for continuous variables depending on the normality of distribution of the parameters (Kolmogorov-Smirnov) or the Pearson's chi-squared test for categorical variables. Multivariable logistic regression model was used to explore the risk factors associated with exitus. We calculated Kaplan-Meier survival estimates and used the log-rank test to compare groups in terms of survival. A two-sided α of less than 0.05 was considered statistically significant. Data were analyzed using SPSS software (version 24.0 for Windows, IBM, US) and represented in graphics according to R 4.0.2 (R Statistics, Vienna, Austria). This study was conducted using publicly available data released by the Health Service of Castilla-La Mancha (SESCAM); therefore, no ethical approval was needed. Total sample was 12,940 patients with clinical suspicion of COVID-19 who attended one of the 14 public hospitals in Castilla-La Mancha during the study period. The validated cohort was 12,126 patients, of which 9,393 were admitted (596 to ICU and 8,797 to hospital ward) and 2,733 were sent home with follow-up in primary care (Figure 1 ). The mean (SD) age of the sample was 66.4 (17. 3) years and the median were 68 years (IQR, 54-81 years). Homogeneity between sex was observed with respect to age (p=0.716). Gender distribution was 5,667 (46.7%) for women and 6,459 (53.3%) for men. Length of hospital stay was 7 days (IQR, 4-12 days), with a significant difference (p<0.001) between 8 days (IQR, 5-13 days) in men and 7 days (IQR, 4-11 days) in women. Median ICU stay was 15 days (IQR, 8-25 days) and there was no difference between genders. All patient characteristics are listed in Table 1 , with total n of each variable. Mortality rate in men was higher than women (p<0.001) and fatality increased with age when establishing ten-year ranges starting from 40 (p<0.001). This means that, considering the total number of deaths, 60.4% were men compared to 39.6% who were women (p<0.001). As for pre-existing comorbidities, a higher prevalence in men than in women was observed for HBP, cardiac pathology and respiratory pathology. Regarding symptoms, men showed lower prevalence of anosmia, diarrhea and vomiting than women. However, a higher proportion of fever, dyspnea and cough were observed in men. Thorax radiography was performed in 97.7% of the participants. A higher prevalence of lung infiltrates and lymphopenia was obtained in men, as well as a D-dimer score over than 1000 ng/mL. The requirement for ventilatory support (invasive or non-invasive) and the prescription of any of the treatments used, were carried out to a greater extent in men than in women. Comparison between survivors and non-survivors for each study variable is presented in Table 2 . There was a higher proportion of deaths among men than women. This fact increased with age. The deceased showed a higher prevalence of pre-existing comorbidities. Regarding symptoms, there was a higher prevalence of dyspnea in non-survivors. However, a higher proportion of anosmia, diarrhea, vomiting and coughing was observed in survivors. The clinical features of the non-survivors were significantly worse than survivors. In the multiple logistic regression model ( Figure 2 ) it was observed that female sex, anosmia, diarrhea, cough, OH-chloroquine and azithromycin acted as protective factors against exitus by COVID-19. The risk factors that increased the probability of death were: male sex, age over 50 years, obesity, cardiac disease, fever, dyspnea, pulmonary infiltrates, lymphopenia, D-dimer above 1000 ng/mL and mechanical ventilation (invasive and non-invasive). The maximum mortality was 20.2% and was recorded on day 62. Cumulative survival between gender was compared on Figure 3B , with a higher survival rate in women (blue, 75.7%) than in men (red, 72.1%), which made a significant difference in the log-rank test (p<0.001). In Figure 3C , survival was segmented according to hospital/ICU stay or homebound patients. The cumulative survival of patients sent home (in red) was 87.5%. Patients admitted to hospital (green) had a cumulative survival of 70.2% and those admitted to ICU (blue) of 61.2%. The log-rank test showed significant differences between the three groups (p<0.001). Finally, Figure 3D shows how survival probability decreased with increasing age range (p<0.001). The median age of our sample was 68 years, slightly lower than other studies carried out in Spain 1,10 , Italy 9 or United Kingdom 12 , but higher than other reports from China 4,5,13 , the US 8 or As in previous studies from UK or other regions of Spain, we have found that some symptoms and comorbidities increase the risk of exitus, such as obesity, cardiac pathology 12 , fever or dyspnea 7,10 . Moreover, in our work we could observe that anosmia, diarrhea and cough were related to low rates of mortality. This could justify the low percentage of these symptoms found in our cohort, J o u r n a l P r e -p r o o f 9 as it is mainly composed by severe patients who came to the hospital. Therefore, the patient's symptoms could help us to stratify the severity of COVID-19 patients on health care demand. The D-dimer average level of our patients is above most national 1 and international 4 series, which is indicative of the severity of the patients included in this work 16 . In our cohort we can establish as associated factors of exitus: lung infiltrates, lymphopenia and D-dimer > 1000 ng/ml. Other In our study we found a significant difference in the survival of patients who were treated with chloroquine (p<0.001) and azithromycin (p<0.001). Recently, in a multinational registry analysis 23 no benefit of hydroxychloroquine or chloroquine (used alone or with a macrolide) could be confirmed in the hospital outcomes for COVID-19. These drug regimens were associated with decreased in-hospital survival and increased frequency of ventricular arrhythmias when used for the treatment of COVID-19 24-28 so they have been subsequently retracted 23 . Therefore, it is necessary to gain more randomized controlled trial evidence prior to the incorporation of hydroxychloroquine and azithromycin into treatment guidelines. Like in other studies, the use of these antiretroviral treatments 29 , anti-inflammatory cytokines (i.e. interferon) 30 or Tocilizumab 31 did not demonstrate a significant decrease in mortality in our study population (Table: 2). It has been reported that an early short course of corticosteroids in patients with moderate to severe COVID-19 improved clinical outcomes. In fact, its use has been implemented for the treatment of COVID-19 [32] [33] [34] . However, for patients with severe COVID-19 but without ARDS, confirmation regarding benefit from different bodies of evidence is inconsistent and of very low quality 35 . In our work, no significant differences were found, possibly due to the lack of standardization in dose and timing of corticosteroids administration. A higher and earlier mortality rate was observed in patients admitted to hospital, which stabilized from approximately day 10 ( Figure 3C ). The ICU survival probability reduces later than the hospital mortality rate during the time of admission, but faster than the hospital mortality from day 23. This may be due to the increased medical attention received by ICU patients, which kept them alive in the first few days in higher proportion than patients on the hospital ward 36 . Mortality rate in our cohort was lower than in other regions of the US 8 , UK 12 , Spain 1,7 and China 4 but higher than in other studies also developed in China or Italy 1, 9, 37 . The variations in the different mortality rates could be due to the preferential inclusion of severe cases during the maximum emergency situation which could correspond to the profile of people seeking medical care and therefore lead to a fatal outcome 3 . Moreover, mortality rates discrepancies may be due to differences in each health care system and data collection. We acknowledge some limitations. First, it could not be confirmed by laboratory testing that all patients were positive for PCR due to the collapse of the health system. Second, the final date of the study was May 11. The status of all patients was reviewed on that date. There was no followup after this date, so the mortality rate could be higher and was not recorded later. Third, the high prevalence of the disease led to priority being given to the care of the most severe patients. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet Assessing the age-and genderdependence of the severity and case fatality rates of COVID-19 disease in Spain Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Covid-19: risk factors for severe disease and death A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain The need for an independent evaluation of the COVID-19 response in Spain. The Lancet Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study Characteristics of COVID-19 infection in Beijing Impact of sex and gender on COVID-19 outcomes in Europe Coronavirus Disease 2019 (COVID-19) in Italy Dynamic relationship between D-dimer and COVID-19 severity Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19 Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Potential therapeutic agents against COVID-19: What we know so far Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial Tocilizumab for severe COVID-19: a systematic review and meta-analysis Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study World Health Organization. Corticosteroids for COVID-19 Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, communityacquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Clinical Characteristics of Coronavirus Disease 2019 in China Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases Characteristics No./No. (%) All patients Women Men p-value (men vs women) a Exitus Cardiac pathology 3006/12109 (24.8) HBP: High Blood Pressure. a Pearson's Chi-square test Significant differences were considered when p<0.001 according to the Fisher Chi-square test Preexisting HBP: High Blood Pressure. a Pearson's Chi-square test. b Multivariate Logistic Regression We thank all health-care workers involved in the diagnosis and treatment of patients in Castilla-La Mancha. We also acknowledge the COVID-19 SESCAM Network and all the public hospitals engaged in this study. This work is supported by the Spanish Ministry of Health and the General Directorate of Public Health of Castilla-La Mancha. Leticia Serrano-Oviedo is the recipient of a contract made by the Directorate of Public Health of Castilla-La Mancha specifically devoted to study the COVID-19 pandemic. The authors declare that they have no competing interests.